Silver Book Fact

The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but no optic, disc or visual field deterioration.

Kass, Michael A., Dale K. Heuer, Eve J. Higginbotham, Chris A. Johnson, John L. Keltner, J. Philip Miller, Richard K. Parrish, M. Roy Wilson, and Mae O. Gordon. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002; 120(6): 701-13. http://archopht.ama-assn.org/cgi/content/abstract/120/6/701

Reference

Title
The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
Publication
Archives of Ophthalmology
Publication Date
2002
Authors
Kass, Michael A., Dale K. Heuer, Eve J. Higginbotham, Chris A. Johnson, John L. Keltner, J. Philip Miller, Richard K. Parrish, M. Roy Wilson, and Mae O. Gordon
Volume & Issue
Volume 120, Issue 6
Pages
701-13
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Tele-ophthalmology
    Adequately trained general practitioners can screen for DR with 90% sensitivity using tele-ophthalmology.  
  • The ACCORD Eye Study found that combination lipid therapy with a fibrate and statin (compared with statin treatment alone) reduced progression of diabetic retinopathy in type 2 diabetics by around…  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus…  
  • The prevalence of age-related macular degeneration (AMD) in the 40 and older population has decreased from an estimated 9.4% from 1988 to 1994, to 6.5% for 2005 to 2008.